Second annual Harvard FUSION symposium explores the Science and Business of Combating Antibiotic Resistance

Harvard scientists identify spark plug that ignites nerve cell damage in Lou Gehrig’s disease

Research alliance will advance small-molecule therapy for most common form of acute leukemia, targeting proteins involved in transcriptional regulation.

UCB-funded Harvard study describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.